Founded in 2020, Anviron is a University Co-founded team of oncologists and biochemest specializing in the glycobiome, an emerging area of study that relates protein synthesis & development to human diseases such as cancer.
We are a team of entrepreneurial and passionate scientists, doctors, and clinicians that are dedicated to bringing our promising therapies to light.
IN THE NEWS
October 26, 2023 - United States Patent issues for Anviron's ANV322, "DPAGT1 inhibitors of capuramycin analogues and their antimigratory activities of solid tumors". - https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230340006
September 5th, 2023 - Anviron initiates study of ANV221 & ANV322 in combination with trastuzumab in HER2+, drug resistant breast cancers.
August 23, 2023 - Jing Yang, PhD joins Anviron board of advisors. Dr. Yang is a Professor of Pharmacology at the UC San Diego and specializes in breast cancers and drivers of invasion and metastasis. - https://pharmacology.ucsd.edu/faculty/department-faculty/jing-yang.html
August 18, 2023 - Japan Patent issues for Anviron's ANV221, "Glycosyl Transferase Inhibitors For Treatment Of Solid Tumors". - Japanese Patent No.: 7334183
July 17, 2023 - The Journal of Clinical Investigation publishes a large, multi-university breast cancer study that established the link between DPAGT1 and drug resistance in HER2+ breast cancer. DPAGT1 inhibition reversed drug resistance and significantly shrank tumors in HER2+ breast cancers. Anviron launch candidates named in the study. - https://www.jci.org/articles/view/164428
June 2, 2023 - Orange County Business Journal names Anviron Co-founder to the OC50, acknowledging the top innovators in the Southern California region. - https://www.ocbj.com/special-report/oc-50/2023-bradley-morrison/
Mar 7, 2023 - United States Patent for Anviron's ANV221 issues for Anviron's "Glycosyltransferase inhibitors for the treatment of solid tumors." - https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11597743
Dec 5, 2022 - ANV221, FDA Orphan Drug candidate for the treatment of Pancreatic Cancer is featured in Orange County Business Journal - https://www.ocbj.com/start-ups-2/startups-innovations-201/
Nov 17-18, 2022 - Anviron Founder participates in invitation-only, Born in California, a University of California innovation event. "California produces more startups every year than any other state. ” said Matt Hanson, Ph.D., director of New Ventures at Applied Innovation. “Many of those companies — in fact, many Fortune 500 companies and unicorns — were founded by University of California alumni. The Born in California demo days is an important and valuable event for bringing our founders and funders together to launch and grow companies that can put a dent in the universe.”
Jul 25, 2022 - Physician, researcher and pioneer oncologist Jack Singer M.D. joins Anviron Board of Advisors. Dr. Singer is former Chief of Medical Oncology with the Seattle VA hospital where he piloted what would become the marrow transplante program of the entire VA system, an important procedure in restoring patient bone marrow after cytotoxic chemotherapy. As founder and Chief Science Officer of Cell Therapeutics, Dr. Singer was responsible for drug discovery including several IND, and NDA applications for oncology candidates. Dr. Singer is a Professor of Oncology at Washington State University, College of Medicine.
Oct 12, 2021 - The United States Food and Drug Administration (FDA) has granted “Orphan Drug Designation” to our drug candidate ANV221 for the treatment of pancreatic cancers. This important milestone confers the benefit of seven (7) years of market exclusivity in the United States and validates the team’s hard work toward developing a promising therapy for this difficult to treat disease.
Mar 18, 2021 - UTRF, UTHSC, and Anviron Partner to Commercialize Novel Treatment for Pancreatic Cancer - The University of Tennessee Research Foundation, the University of Tennessee Health Science Center and biotech therapeutics startup Anviron recently announced a partnership to commercialize a novel product candidate with promising efficacy against pancreatic cancer tumors.
Dec 28, 2020 - University of Tennessee Research Foundation & Anviron announce agreement to an exclusive, world-wide license to commercialize a novel low toxicity DPAGT-1 inhibitor with demonstrated in vivo efficacy against pancreatic cancer tumors.
Anviron Co-founder, Bradley Morrison discusses how his team is exploiting important vulnerabilities in breast and pancreatic cancers.
- University of California, Irvine